Table 3.

Common treatment-related adverse events (≥20%) occurred in patients with bone metastases.

	All grades		Grade 3 or worse
Adverse events n(%)	Anlotinib (n=29)	Placebo (n=18)	Anlotinib (n=29)	Placebo (n=18)
All	29 (100.0)	18 (100.0)	17 (58.6)	9 (50.0)
Palmar-plantar erythrodysesthesia syndrome	19 (65.5)	7 (38.9)	4 (13.8)	2 (11.1)
Proteinuria	18 (62.1)	7 (38.9)	0 (0.0)	0 (0.0)
Hypertension	16 (55.2)	6 (33.3)	1 (3.5)	2 (11.1)
QT interval prolongation	15 (51.7)	2 (11.1)	0 (0.0)	0 (0.0)
Diarrhea	13 (44.8)	8 (44.4)	2 (6.9)	0 (0.0)
Hypertriglyceridemia	12 (41.4)	7 (38.9)	2 (6.9)	0 (0.0)
Fatigue	12 (41.4)	5 (27.8)	2 (6.9)	0 (0.0)
Hypercholesteremia	11 (37.9)	4 (22.2)	0 (0.0)	1 (5.6)
ALT increase	11 (37.9)	1 (5.6)	1 (3.5)	0 (0.0)
Pharyngalgia	10 (34.5)	4 (22.2)	1 (3.5)	1 (5.6)
Urine erythrocyte positive	10 (34.5)	4 (22.2)	0 (0.0)	0 (0.0)
GGT elevation	10 (34.5)	1 (5.6)	1 (3.5)	0 (0.0)
LDL increase	10 (34.5)	1 (5.6)	0 (0.0)	0 (0.0)
Hoarseness	10 (34.5)	0 (0.0)	0 (0.0)	0 (0.0)
Lipase elevation	9 (31.0)	5 (27.8)	3 (10.3)	2 (11.1)
Anorexia	8 (27.6)	5 (27.8)	1 (3.5)	0 (0.0)
AST increase	8 (27.6)	2 (11.1)	0 (0.0)	0 (0.0)
Conjugated bilirubin increase	7 (24.1)	1 (5.6)	1 (3.5)	0 (0.0)
Lipase elevation	6 (20.7)	6 (33.3)	2 (6.9)	2 (11.1)
Platelet count decrease	6 (20.7)	1 (5.6)	1 (3.5)	0 (0.0)
LDH increase	6 (20.7)	0 (0.0)	1 (3.5)	0 (0.0)
Bilirubin increase	5 (17.2)	2 (11.1)	0 (0.0)	0 (0.0)
Neutrophil count decrease	5 (17.2)	2 (11.1)	0 (0.0)	0 (0.0)
Back pain	5 (17.2)	1 (5.6)	0 (0.0)	0 (0.0)
White blood cell count decrease	4 (13.8)	3 (16.7)	0 (0.0)	0 (0.0)
Toothache	4 (13.8)	3 (16.7)	0 (0.0)	0 (0.0)

GGT γ-Glutamyltransferase, ALT alanine aminotransferase, AST aspartate aminotransferase, LDH lactate dehydrogenase.